Biohaven (BHVN) stock soars 70% after Q1 results, Pfizer’s (PFE) buy offer

Follow us on Google News:
 Biohaven (BHVN) stock soars 70% after Q1 results, Pfizer’s (PFE) buy offer
Image source: © Kadmy |


  • Drugmaker Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) net product revenue grew 182% YoY to US$123.6 million in the quarter ended March 31, 2022.
  • On Tuesday, Pfizer announced acquiring Biohaven for US$11.6 billion in cash.
  • The BHVN stock gained 20% in one year.

Shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) shot up by 70.79% to US$141.995 in the premarket on Tuesday after declaring its first-quarter fiscal 2022 results and Pfizer Inc’s (PFE) cash offer of US$11.6 billion to acquire the vaccine maker.

Pfizer Deal

Pfizer Inc on Tuesday announced plans to acquire migraine drugmaker Biohaven Pharmaceutical Holding Company Ltd for US$11.6 billion in cash.

It will give Pfizer access to Biohaven’s approved drug Rimegepant, marketed as Nurtec ODT in the US. Rimegepant was approved for severe migraine treatment in 2020. In May 2021, it won expanded approval for the drug to prevent migraine episodes. 

As part of the deal, Pfizer will acquire all the outstanding Biohaven shares, which it has not yet owned, for US$148.50 per share in cash, at a 78.6% premium on its last closing price. Pfizer holds a 2.6% stake in the company. 

Also Read: RTX to LHX: 5 aerospace, defense stocks with 2-digit 1-year return

Biohaven (BHVN) stock soars 70% after Q1 results, Pfizer’s (PFE) buy offer

Also Read: Top mental health stocks to watch in Q2: LLY, ACHC, ITCI, LSFT & ACAD


Biohaven reported net product revenue of US$123.6 million in the first quarter ended March 31, 2022, compared to US$43.8 million in the previous year. The 182% increase in revenue YoY was due to increased sales volume of its prescription drug, Nurtech ODT, and net price realization due to lesser sales allowances.

The ‘collaboration and other’ revenue came in at US$195.3 million for Q1, 2022, compared to zero revenue under ‘collaboration and other’ in the same quarter in 2021.

Also Read: 5 MedTech stocks to explore as covid cases surge: VEEV to TDOC

Biohaven’s net loss attributable to common shareholders was US$209.1 million or US$2.97 per share diluted, compared to a net loss attributable to the company of US$265.0 million or US$4.27 per share diluted, in the March quarter of 2021.

It reported cash and equivalents and marketable securities of US$602.5 million as of March 31, 2022, versus US$364.6 million as of December 31, 2021. 

Also Read: 5 agriculture stocks to explore as food inflation spikes: ADM to FMC

In January, the company received US$500 million in upfront proceeds from Pfizer, including US$150.0 million in cash and US$350.0 million in Biohaven common shares purchase proceeds as part of their strategic collaboration arrangement.

The New Haven, Connecticut-based commercial-stage biopharma company boasts a portfolio of innovative therapies and late-stage product candidates targeting patients with neurological and neuropsychiatric diseases. 

Also Read: CELU to CMPI: Explore top 5 biotech stocks with over 100% YTD return

Bottom line:

Biohaven’s market capitalization is US$5.9 billion. The stock traded in the range of US$151.51 to US$65.24 in one year. It closed at US$83.14 on May 9. BHVN gained 20% in one year.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Featured Articles